CTOs on the Move

Nutritional Laboratories International

www.nutritionallabs.com

 
NLI offers: , Drug cGMP quality manufacturing processes , Superior laboratory support services following current Good Manufacturing Practices (cGMPs) , Disciplined and documented product design and engineering systems , Information-based customer
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Children's Crisis Treatment Center

CCTC passionately serves the emotional needs of children and families at risk beginning in early childhood.

ANI Pharmaceuticals Inc

ANI Pharmaceuticals Inc is a Baudette, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Anuncia

Anuncia Medical, Inc., an emerging leader in Cerebrospinal Fluid (CSF) management

Trimel Pharmaceuticals

Trimel Pharmaceuticals Corporation is a Canadian specialty pharmaceutical company focused on bringing innovative products to market that improve the patient experience and produce strong investor returns. The Corporation holds a licence for the development and marketing rights to certain products utilizing a bioadhesive intranasal gel drug delivery technology platform and owns a novel unit-dose dry powder inhaler/nasal dispersion system (“TriVair™”). The Corporation is focussing its present efforts on the development and application of these technologies for therapeutic categories such as (a) male hypogonadism (“low testosterone” or “Low-T”) and (b) female orgasmic disorder. Additionally, the Corporation owns the Canadian rights to ESTRACE® and is overseeing its distribution and marketing in Canada. The Corporation’s present drug delivery technology platforms are intended to create products that are expected to be innovative, safer, possibly more effective, easier to use and more practical than competitive products on the market.

Aeon Biopharma

Aeon Biopharma is leading the way as the first and only company focused solely on toxins for therapeutic applications. We are innovating toxin use to improve the lives of patients who are suffering from debilitating medical disorders. AEON is excited to introduce ABP450, the first 900 kDa toxin innovation in the US for over 30 years, and is proud to partner with physicians to advance treatment options. We are dedicated to enhancing patient lives by leading in new ways to use toxins while improving existing toxin therapy.